- Marvel Biosciences Corp. (MRVL) and its wholly owned subsidiary, Marvel Biotechnology, have announced a non-brokered private placement for gross proceeds of up to $700,000
- The units will be offered at a price of $0.10 per unit
- Each unit will consist of one common share in the capital of the company and one common share purchase warrant
- The proceeds of the offering will be used to fund drug formulation, toxicology studies and for general working capital purposes
- Marvel Biosciences Corp is a life sciences company focused on the discovery and the development of a synthetic derivative compound of a known proven drug
- Marvel Biosciences Corp. was unchanged, trading at $0.10 at 11:42 AM ET
Marvel Biosciences Corp. (MRVL) and subsidiary, Marvel Biotechnology, have announced a non-brokered private placement.
The company will issue units priced at $0.10 for gross proceeds of up to $700,000.
Each unit will consist of one common share in the capital of the company and one common share purchase warrant.
Each warrant entitles the holder to purchase one common share at an exercise price of $0.15 on or before the date that is the earlier one year from the date of closing.
Warrants are subject to an acceleration clause.
The company may pay a cash finders’ fee equal up to 8 per cent of the gross proceeds.
The proceeds of the offering will be used to fund drug formulation, toxicology studies and for general working capital purposes.
Marvel Biosciences Corp is a life sciences company focused on the discovery and the development of a synthetic derivative compound of a known proven drug.
Marvel Biosciences Corp. was unchanged, trading at $0.10 at 11:42 AM ET.
